|

PD-L1 antibody Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2/3: 1

Top Sponsors

  • N.N. Alexandrov National Cancer Centre1

Indications

  • Persistent Cervical Cancer1
  • Recurrent Cervical Cancer1
  • Metastatic Cervical Cancer1
  • Cancer1

Other1 trial

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.